Litigation Details for United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

« Back to Dashboard

United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

Docket	0:20-cv-00686	Date Filed	2020-03-06
Court	District Court, D. Minnesota	Date Terminated	2020-12-03
Cause	15:2 Antitrust Litigation	Assigned To	David Singleton Doty
Jury Demand	Plaintiff	Referred To	Elizabeth Cowan Wright
Patents	6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622
Link to Docket	External link to docket

Details for United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-06				External link to document
2020-03-06	1		to a patient while Thalomid ‘501 Patent 6,045,501 28-Aug- 4-Apr-00 28-Aug- preventing…800 patent, ‘217 patent, ‘569 patent, ‘498 patent, ‘095 patent, ‘621 patent, and the ‘622 patent.89 …800 patent, ‘217 patent, ‘569 patent, ‘498 patent, ‘095 patent, ‘621 patent, and the ‘622 patent.90 …‘501 patent, the ‘976 patent, the ‘432 patent, the ‘984 patent, the ‘763 patent, the ‘188 patent, the…‘720 patent, the ‘977 patent, the ‘784 patent, the ‘399 patent, the ‘018 patent, the ‘566 patent, the	External link to document

UnitedHealthcare Services v. Celgene: Litigation Summary and Patent-Strategy Analysis

Last updated: August 31, 2026

UnitedHealthcare Services, Inc. v. Celgene Corporation, No. 0:20-cv-00686, is an antitrust action concerning Celgene’s conduct involving Revlimid, the lenalidomide product used primarily in multiple myeloma and related hematologic cancers. UnitedHealthcare alleged that Celgene used its patent portfolio, generic settlements, restricted-distribution arrangements, and the FDA Risk Evaluation and Mitigation Strategy, or REMS, for Revlimid to delay or restrict generic competition.

The case is important because it targets the commercial structure surrounding Revlimid rather than asserting ordinary patent infringement. The principal exposure involved alleged overcharges paid by health plans and other purchasers before broader generic lenalidomide entry.

What is UnitedHealthcare Services v. Celgene about?

UnitedHealthcare alleged that Celgene maintained monopoly power over lenalidomide by combining patent litigation settlements with agreements that limited generic manufacturers’ ability to launch competing products.

Revlimid’s active ingredient, lenalidomide, is a thalidomide analogue developed by Celgene. Celgene became a Bristol Myers Squibb subsidiary following BMS’s acquisition of Celgene in November 2019. The complaint focused on conduct occurring before and after the acquisition and named Celgene as the principal defendant.

The alleged conduct included:

• Enforcement of multiple Revlimid patents against generic manufacturers.
• Settlements with generic companies that allegedly delayed market entry.
• Restrictions on access to lenalidomide samples and commercial quantities.
• Use of the Revlimid REMS program to make generic development and bioequivalence testing more difficult.
• Commercial practices that allegedly preserved Celgene’s monopoly after the earliest composition patents expired.

UnitedHealthcare sought damages under federal antitrust law and related relief based on payments for Revlimid at allegedly supracompetitive prices. The action was filed in the U.S. District Court for the District of Minnesota under Case No. 0:20-cv-00686.

Which drug and patents are central to the case?

Revlimid and lenalidomide

Revlimid is approved for several indications, including:

• Multiple myeloma in combination regimens.
• Maintenance treatment following autologous hematopoietic stem-cell transplantation.
• Myelodysplastic syndromes associated with a deletion 5q abnormality.
• Mantle cell lymphoma after prior therapy.

The relevant product is a small-molecule drug, not a biologic. Biosimilar litigation concepts therefore do not apply directly. Generic lenalidomide products are approved through abbreviated new drug applications, or ANDAs.

The patent dispute surrounding Revlimid involved a layered estate rather than one controlling composition patent. The portfolio included patents directed to:

• Lenalidomide and related chemical subject matter.
• Pharmaceutical compositions.
• Dosing regimens.
• Treatment methods.
• Safe-use and distribution systems.
• Indication-specific methods of treatment.

Celgene’s strongest commercial leverage came from the combination of patents with a controlled distribution system. Even where an individual patent had limited remaining life, the aggregate portfolio could affect generic launch timing and settlement economics.

Orange Book relevance

Revlimid patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, were relevant to ANDA certifications and patent litigation. A generic applicant filing an ANDA may certify that an Orange Book patent is invalid, unenforceable, or not infringed under Paragraph IV.

The case did not function as a conventional Paragraph IV infringement action brought by Celgene against a generic applicant. UnitedHealthcare was a payer and purchaser, not an ANDA filer. Its theory was that Celgene used patent litigation and related agreements in an anticompetitive manner.

The Orange Book remained relevant because the patents and certifications created the legal framework for generic challenges, settlement negotiations, and potential launch dates.

What antitrust conduct did UnitedHealthcare challenge?

UnitedHealthcare’s theory was that Celgene’s conduct delayed generic competition beyond the date that would have resulted from ordinary patent enforcement.

The complaint alleged that Celgene:

1. Filed or threatened patent litigation against prospective generic entrants.
2. Reached agreements that delayed generic launches.
3. Used restricted distribution and REMS requirements to impede generic testing.
4. Prevented generic manufacturers from obtaining sufficient product samples.
5. Preserved high Revlimid prices after Celgene’s core exclusivity had weakened.
6. Caused purchasers such as UnitedHealthcare to pay more than they would have paid in a competitive market.

The central economic question was whether the challenged agreements reflected legitimate patent settlements or instead constituted unlawful market-allocation or delayed-entry arrangements.

How did the case relate to Paragraph IV challenges?

Paragraph IV litigation created the entry dates that UnitedHealthcare contended were unlawfully delayed.

A generic applicant may challenge an Orange Book patent before patent expiration by filing a Paragraph IV certification. The filing can trigger patent litigation and, under the Hatch-Waxman framework, a 30-month stay of FDA approval in certain circumstances. The resulting litigation often ends in one of three ways:

• A judgment that the patent is valid and infringed.
• A judgment that the patent is invalid or not infringed.
• A settlement establishing a negotiated launch date and other commercial terms.

UnitedHealthcare’s complaint treated the settlement framework as part of the alleged anticompetitive scheme. The payer’s position was that certain generic companies could have entered earlier or competed more aggressively absent the challenged agreements.

The distinction is material. A patent settlement is not automatically unlawful merely because it delays generic entry. The antitrust analysis depends on the strength and scope of the patent claims, the consideration exchanged, the agreement’s restrictions, and the likely counterfactual entry date.

What role did Revlimid’s REMS program play?

Revlimid was subject to a controlled distribution program designed to reduce fetal-exposure risks associated with lenalidomide. Celgene operated the Revlimid REMS program under FDA oversight.

UnitedHealthcare alleged that Celgene used the REMS structure to restrict generic manufacturers’ access to samples needed for development and testing. The complaint characterized these restrictions as a barrier that made it more difficult for generic companies to complete bioequivalence studies and obtain FDA approval.

This theory had two dimensions:

• A regulatory dimension involving REMS administration and sample access.
• An antitrust dimension involving whether Celgene intentionally used the program to exclude competitors.

The FDA’s approval of a REMS does not itself resolve whether a manufacturer’s administration of the program violates antitrust law. The relevant question is whether the manufacturer used a legitimate safety system to achieve an exclusionary commercial effect.

What was the procedural history?

Event	Significance
May 2020	UnitedHealthcare filed the action in the District of Minnesota under No. 0:20-cv-00686.
2020 onward	The action became part of broader litigation concerning Revlimid and related Celgene conduct.
Pretrial proceedings	The dispute involved motions concerning pleading sufficiency, standing, antitrust injury, causation, and the effect of patent settlements.
Ongoing litigation framework	Revlimid-related claims were coordinated with other private antitrust actions in federal court proceedings addressing generic entry and Celgene’s commercial practices.

The action should be distinguished from individual patent cases brought against ANDA filers. The UnitedHealthcare matter is a purchaser antitrust action. Its damages theory requires proof that the challenged conduct caused delayed competition and inflated Revlimid payments.

What litigation defenses did Celgene have?

Celgene’s principal defenses were expected to include the following.

Lawful patent exclusion

Celgene could argue that generic entry was delayed by valid patents, not unlawful conduct. A patent holder generally may exclude competitors within the lawful scope and duration of its patent rights.

No anticompetitive agreement

Celgene could contend that its generic settlements were ordinary compromises of patent litigation. Settlement agreements can reduce litigation costs and establish predictable entry dates without violating antitrust law.

Lack of antitrust injury

Celgene could challenge whether UnitedHealthcare proved that the agreements, rather than valid patent rights or other market conditions, caused higher prices.

Standing and purchaser issues

The case raised potential questions concerning UnitedHealthcare’s position in the distribution chain and whether it could recover under federal antitrust law for the purchases at issue. The analysis depended on the contractual and payment structure used for Revlimid transactions.

REMS and safety justification

Celgene could argue that its distribution controls reflected legitimate patient-safety requirements and FDA compliance obligations rather than exclusionary conduct.

What was the commercial exposure for UnitedHealthcare and other payers?

Revlimid was one of Celgene’s largest products before the BMS transaction. Its high price and broad use in oncology made generic entry economically significant for health plans, pharmacy benefit managers, government programs, and patients.

The financial impact depended on:

• The number of covered Revlimid prescriptions.
• The net price after rebates and discounts.
• The launch date of each generic product.
• Whether generic entry was limited by volume restrictions.
• The number of competing generic manufacturers.
• The price erosion following broader entry.
• The duration of any alleged overcharge period.

Limited generic entry can produce less price erosion than a fully competitive market. A negotiated launch with restricted quantities may generate savings while still leaving the branded manufacturer with substantial market power.

For damages purposes, UnitedHealthcare would need to establish a counterfactual market. That could involve comparing actual Revlimid prices with prices that would have prevailed under earlier generic entry or with prices observed after multiple generic suppliers entered.

When did generic lenalidomide enter the market?

Generic lenalidomide began entering the U.S. market in limited form in 2022 under settlements between Celgene and generic manufacturers. The initial launches were not equivalent to unrestricted multi-source generic competition. Entry was structured through negotiated dates, volume limitations, or other conditions.

Broader competition developed over time as additional generic manufacturers launched. The commercial effect therefore occurred in stages:

1. Branded Revlimid monopoly or near-monopoly.
2. Limited generic entry under settlement terms.
3. Increasing generic availability.
4. Greater price erosion as more suppliers entered.
5. Long-term competition after the principal patent and settlement barriers expired.

The staged-entry pattern was central to the damages and liability theories in Revlimid antitrust litigation.

What is the patent strength of the Revlimid estate?

The Revlimid estate was commercially strong but structurally vulnerable.

Estate characteristic	Litigation impact
Early composition patents	Supported initial exclusivity but had limited remaining life by the time of later litigation.
Method-of-use patents	Extended protection for specific indications and patient populations.
Dosing patents	Could restrict particular treatment schedules even when broader chemical claims were unavailable.
REMS and distribution controls	Created a non-patent barrier to generic development and testing.
Multiple generic challengers	Increased invalidity, non-infringement, and antitrust pressure.
Settlement agreements	Converted uncertain patent outcomes into negotiated launch dates but created antitrust scrutiny.

The estate’s practical strength depended less on any single patent than on cumulative enforcement, indication coverage, settlement timing, and access to product samples.

Did the case involve biosimilar risk?

No. Revlimid is a small-molecule drug, so the direct competitive threat was from generic lenalidomide under the ANDA pathway, not biosimilars under the Biologics Price Competition and Innovation Act.

The relevant regulatory risks were:

• Paragraph IV patent challenges.
• FDA approval of ANDAs.
• REMS compliance.
• Restricted sample access.
• Limited-launch settlements.
• Generic manufacturing and supply capacity.

What is the current litigation significance?

The case is significant for three reasons.

First, it tests whether a payer can use antitrust law to challenge a branded manufacturer’s combined use of patents, settlements, and REMS controls.

Second, it addresses the counterfactual generic launch problem. Courts must determine when generic entry would have occurred absent the challenged conduct, not merely identify the date on which a generic ultimately launched.

Third, it illustrates the risk created when a drug has a large patent estate and a safety-related distribution system. The same structure that protects patients and supports patent enforcement can become evidence in an antitrust claim if the plaintiff proves that it was administered to obstruct generic development.

Key Takeaways

• UnitedHealthcare’s case is an antitrust and overcharge action, not a conventional patent-infringement case.
• Revlimid, or lenalidomide, is the central product.
• The challenged conduct involved patent settlements, generic entry restrictions, and Celgene’s REMS program.
• UnitedHealthcare alleged that Celgene delayed competition and caused payers to overpay.
• Paragraph IV litigation supplied the patent framework for generic challenges and negotiated launch dates.
• Generic lenalidomide entered in stages beginning in 2022, limiting the immediate price impact of competition.
• Biosimilar risk is not relevant because lenalidomide is a small molecule.
• The principal damages issue is the counterfactual date and conditions of generic entry.
• The principal liability issue is whether Celgene’s conduct exceeded lawful patent and safety-related activity.

FAQs

Was UnitedHealthcare a direct purchaser of Revlimid?

UnitedHealthcare alleged that it paid for or reimbursed Revlimid purchases and therefore suffered antitrust overcharges. The precise standing analysis depended on the transaction and reimbursement arrangements at issue.

Did UnitedHealthcare challenge the validity of a specific Revlimid patent?

No. The action challenged Celgene’s broader conduct involving patents, generic settlements, and distribution controls. It was not a standalone declaratory judgment action seeking invalidity of one identified patent.

Why are generic settlement agreements important in the case?

Settlement agreements can establish generic launch dates. UnitedHealthcare alleged that the agreements delayed competition beyond the date that would have resulted from ordinary patent litigation outcomes.

Does FDA approval of the Revlimid REMS program protect Celgene from antitrust liability?

No. FDA approval addresses regulatory safety requirements. It does not automatically resolve whether the program was administered in an exclusionary or anticompetitive manner.

What would make the case most valuable to generic drug manufacturers?

A finding that REMS restrictions or generic settlements unlawfully delayed access would affect future negotiations involving high-value drugs with restricted distribution systems. It could increase pressure for earlier generic access and greater transparency in settlement terms.

References

1. Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene.
2. U.S. District Court for the District of Minnesota. (2020). United HealthCare Services, Inc. v. Celgene Corporation, No. 0:20-cv-00686.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (n.d.). Risk evaluation and mitigation strategies.
5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
6. U.S. Food and Drug Administration. (n.d.). Revlimid prescribing information.